西地那非
他达拉非
伐地那非
cGMP特异性磷酸二酯酶5型
医学
肺动脉
肺动脉高压
交叉研究
安慰剂
血流动力学
磷酸二酯酶
血压
双盲
心脏病学
随机对照试验
内科学
药理学
化学
替代医学
酶
病理
生物化学
作者
Masashi Sakuma,Kunio Shirato
出处
期刊:PubMed
日期:2008-11-01
卷期号:66 (11): 2157-61
被引量:1
摘要
The therapeutic effects of phosphodiesterase type 5 inhibitors in patients with pulmonary arterial hypertension (PAH) were reviewed. A double-blind, placebo-controlled study named SUPER-1 showed that sildenafil improved exercise capacity, WHO functional class, hemodynamics, and quality of life. Two randomized, double-blind, crossover studies, showed that sildenafil improved exercise tolerance and quality of life, and reduced estimated pulmonary artery systolic pressure. The dose independent effects of sildenafil on PAH are controversial. There are few case-reports that show vardenafil and tadalafil have benefits in PAH patients. A double-blind study of tadalafil in PAH patients is ongoing.
科研通智能强力驱动
Strongly Powered by AbleSci AI